Skip to main content

Peer Review reports

From: A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study)

Original Submission
28 Apr 2022 Submitted Original manuscript
19 May 2022 Reviewed Reviewer Report
30 May 2022 Reviewed Reviewer Report
7 Jun 2022 Reviewed Reviewer Report - James Andrew Watson
6 Jul 2022 Author responded Author comments - Taku Kinoshita
Resubmission - Version 2
6 Jul 2022 Submitted Manuscript version 2
10 Jul 2022 Reviewed Reviewer Report
11 Jul 2022 Reviewed Reviewer Report
28 Jul 2022 Author responded Author comments - Taku Kinoshita
Resubmission - Version 3
28 Jul 2022 Submitted Manuscript version 3
2 Aug 2022 Author responded Author comments - Taku Kinoshita
Resubmission - Version 4
2 Aug 2022 Submitted Manuscript version 4
5 Aug 2022 Author responded Author comments - Taku Kinoshita
Resubmission - Version 5
5 Aug 2022 Submitted Manuscript version 5
Publishing
5 Aug 2022 Editorially accepted
27 Sep 2022 Article published 10.1186/s12916-022-02518-7

You can find further information about peer review here.

Back to article page